Clinical Trial

A Study to Investigate the Effects of JMKX003142 on QTc Interval in Healthy Adults

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 13, 2026 (before its estimated May 14, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this study is to assess the effect of a therapeutic and supratherapeutic oral dose of JMKX003142 on the corrected cardiac QT interval relative to a placebo in healthy participants
Trial Details
NCT Number NCT07470177
Lead Sponsor Jemincare
Collaborators: Zhejiang Hangyu Pharmaceutical Co., Ltd.
Conditions ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Enrollment 24 participants
Start Date 2026-03-27
Primary Completion 2026-05-14 (estimated)
Study Completion 2026-06-23 (estimated)
Updated on ClinicalTrials.gov 2026-03-13